BR0013219A - Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto - Google Patents

Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto

Info

Publication number
BR0013219A
BR0013219A BR0013219-5A BR0013219A BR0013219A BR 0013219 A BR0013219 A BR 0013219A BR 0013219 A BR0013219 A BR 0013219A BR 0013219 A BR0013219 A BR 0013219A
Authority
BR
Brazil
Prior art keywords
treating
inhibiting
nsaid
kinase inhibitor
pharmaceutical composition
Prior art date
Application number
BR0013219-5A
Other languages
English (en)
Inventor
Philip Frost
Carolyn Mary Discafani Marro
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR0013219A publication Critical patent/BR0013219A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODOS DE TRATAMENTO OU INIBIçãO DE PóLIPOS DE CóLON, DE TRATAMENTO OU INIBIçãO DE CâNCER COLORRETAL, USO DE UMA COMBINAçãO DE NSAID E DE UM INIBIDOR DE EGFR QUINASE, COMPOSIçãO FARMACêUTICA, E, PRODUTO". Esta invenção provê um método de tratamento ou inibição de pólipos do cólon ou de tratamento ou inibição de câncer colorretal em um mamífero em necessidade do mesmo, que compreende administrar ao referido mamífero um NSAID e um inibidor de quinase de EFGR.
BR0013219-5A 1999-08-12 2000-08-02 Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto BR0013219A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (1)

Publication Number Publication Date
BR0013219A true BR0013219A (pt) 2002-04-23

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013219-5A BR0013219A (pt) 1999-08-12 2000-08-02 Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto

Country Status (24)

Country Link
EP (1) EP1202746B1 (pt)
JP (1) JP2003507342A (pt)
KR (1) KR20020018201A (pt)
CN (1) CN1229142C (pt)
AR (1) AR029763A1 (pt)
AT (1) ATE341341T1 (pt)
AU (1) AU783116B2 (pt)
BR (1) BR0013219A (pt)
CA (1) CA2380904C (pt)
CZ (1) CZ2002474A3 (pt)
DE (1) DE60031127T2 (pt)
DK (1) DK1202746T3 (pt)
EA (1) EA006876B1 (pt)
ES (1) ES2272305T3 (pt)
HK (1) HK1042244A1 (pt)
HU (1) HUP0203162A3 (pt)
IL (1) IL147913A0 (pt)
MX (1) MXPA02001448A (pt)
NO (1) NO20020663L (pt)
NZ (1) NZ517120A (pt)
PL (1) PL353267A1 (pt)
PT (1) PT1202746E (pt)
WO (1) WO2001012227A1 (pt)
ZA (1) ZA200201156B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
AU4545201A (en) * 2000-03-13 2001-09-24 American Cyanamid Co Method of treating or inhibiting colonic polyps
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
WO2003000705A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
ES2272737T3 (es) 2001-07-16 2007-05-01 Astrazeneca Ab Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
NZ552335A (en) * 2001-10-25 2008-11-28 Novartis Ag Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2542007C (en) 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
US8008003B2 (en) * 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
WO2005117916A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
MX2010012442A (es) 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PL387312A1 (pl) * 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
JP2012520893A (ja) 2009-03-18 2012-09-10 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
BR112013030894A2 (pt) * 2011-06-01 2016-08-16 Janus Biotherapeutics Inc moduladores do sistema imune

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001234T2 (tr) * 1997-11-04 2000-08-21 Pfizer Products Inc. Terapötik aktif bileşiklerde katelkolün indazol biyoisoster değişimi.
AU1308799A (en) * 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps

Also Published As

Publication number Publication date
AR029763A1 (es) 2003-07-16
CN1370080A (zh) 2002-09-18
WO2001012227A1 (en) 2001-02-22
MXPA02001448A (es) 2002-07-02
ES2272305T3 (es) 2007-05-01
NZ517120A (en) 2004-10-29
CA2380904C (en) 2009-02-10
IL147913A0 (en) 2002-08-14
PT1202746E (pt) 2007-01-31
NO20020663L (no) 2002-04-09
ZA200201156B (en) 2003-05-12
KR20020018201A (ko) 2002-03-07
ATE341341T1 (de) 2006-10-15
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
JP2003507342A (ja) 2003-02-25
AU6395900A (en) 2001-03-13
PL353267A1 (en) 2003-11-03
DE60031127D1 (de) 2006-11-16
CZ2002474A3 (cs) 2003-02-12
DE60031127T2 (de) 2007-02-01
EA200200246A1 (ru) 2002-08-29
NO20020663D0 (no) 2002-02-11
EP1202746A1 (en) 2002-05-08
HUP0203162A3 (en) 2006-07-28
HUP0203162A2 (hu) 2003-01-28
CN1229142C (zh) 2005-11-30
HK1042244A1 (zh) 2002-08-09
EP1202746B1 (en) 2006-10-04
DK1202746T3 (da) 2007-01-02
EA006876B1 (ru) 2006-04-28

Similar Documents

Publication Publication Date Title
HK1042244A1 (zh) 包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
PT1286671E (pt) Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
BRPI0415896A (pt) combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia
BR9805544C1 (pt) Uso de um composto.
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
DK1079843T3 (da) Anvendelse af a1beta1 integrinreceptorinhibitorer og TFG beta1 inhibitorer til behandling af nyresygdom
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
BR9707844A (pt) Combinação de desidroepiandrosterona e inibidores de aromatase e emprego desta combinação para a preparação de um medicamento para o tratamento de uma deficiência de androgênio relativa e absoluta no homem
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
DE69901805D1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
BR0114856A (pt) Combinação compreendendo camptotecina e um derivado de estilbeno para o tratamento de câncer
BR0213410A (pt) Usos farmacêuticos de bisfosfonatos
BR0015121A (pt) Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação
BR0310027A (pt) Métodos de empregar uma combinação de uma 3-heteroaril-2-indolinona e um inibidor de ciclooxigenase-2 para o tratamento de neoplasia
SI1202746T1 (sl) FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA
BR0315376A (pt) Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 45/06, A61K 31/505, A61K 31/47, A61P 35/00

Ipc: A61K 45/06 (2011.01), A61K 31/505 (2011.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.